Drug Approval | August 23, 2024
Wanbury receives EIR from FDA for Patalganga facility
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
This product will be manufactured by Indoco at its manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa in India
Coveris’ security labels also work seamlessly with self-checkouts where around 80% of retail sales now typically occur
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients
The emergence of new infections in India is a growing concern
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC) is indicated to relieve redness of the eye due to minor eye irritations.
Subscribe To Our Newsletter & Stay Updated
